Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Elixir Department: SOP for Identification of Holding Time and Conditions – V 2.0

Posted on By

Elixir Department: SOP for Identification of Holding Time and Conditions – V 2.0

Standard Operating Procedure for Identification of Holding Time and Conditions in Elixir Manufacturing

Department Elixir Department
SOP No. SOP/ELX/073/2025
Supersedes SOP/ELX/073/2022
Page No. Page 1 of 8
Issue Date 11/04/2025
Effective Date 15/04/2025
Review Date 11/04/2026

1. Purpose

To define the procedure for determining and monitoring acceptable holding times and conditions for intermediates, bulk solutions, and in-process elixir formulations to ensure product quality and stability.

2. Scope

This SOP applies to all intermediate and final bulk elixir solutions held during manufacturing stages such as post-mixing, pre-filtration, post-filtration, and pre-filling in the Elixir Department.

3. Responsibilities

  • Production Operator:
    • Record holding start and end times, and monitor environmental conditions.
  • Production Supervisor:
    • Ensure batch is held within validated time limits and specified conditions.
    • Initiate deviation process if holding time exceeds permissible limits.
  • QA Officer:
    • Review holding logs and environmental data; provide approval for batch continuation or disposition.
See also  Elixir Department: SOP for Use of Water for Injection (WFI) in Elixir Production - V 2.0

4. Accountability

The Head of Production is accountable for ensuring that product intermediates and bulk elixirs are not held beyond validated times and are maintained under controlled conditions.

5. Procedure

5.1 Determination of Holding Times

  1. Holding times for each product stage shall be defined based on development studies and validated data.
  2. Typical holding times include:
    • Post-mixing (pre-filtration): ≤ 8 hours
    • Post-filtration (pre-filling): ≤ 12 hours
    • Intermediate syrup stages: ≤ 24 hours (if applicable)

5.2 Storage Conditions

  1. Intermediate and bulk solutions shall be stored in closed, labeled stainless steel tanks or containers.
  2. Conditions shall include:
    • Temperature: 20–25°C or as per product-specific requirement
    • Protection from light for light-sensitive formulations
    • Nitrogen blanketing for alcohol-based volatile solutions (if applicable)
See also  Elixir Department: SOP for Use of Transfer Pumps in Manufacturing - V 2.0

5.3 Documentation and Monitoring

  1. Record start and end times of each holding stage in the Holding Time Log (Annexure-1).
  2. Monitor and record temperature every hour using calibrated temperature display units.
  3. Use the Holding Condition Checklist (Annexure-2) to verify compliance.

5.4 Handling Deviations

  1. If holding exceeds the validated time:
    • Immediately inform QA and initiate a deviation report.
    • Hold product under “Quarantine” status pending investigation.
  2. QA will evaluate the impact on product quality and recommend disposition.

6. Abbreviations

  • SOP: Standard Operating Procedure
  • QA: Quality Assurance
  • °C: Degrees Celsius
  • CFU: Colony Forming Units

7. Documents

  1. Holding Time Log (Annexure-1)
  2. Holding Condition Checklist (Annexure-2)
  3. Deviation Report (if applicable)

8. References

  • WHO TRS 986 – GMP for Pharmaceutical Products
  • 21 CFR Part 211.111 – Time Limitations on Production
See also  Elixir Department: SOP for Prevention of Aeration During Mixing - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Holding Time Log

Date Batch No. Stage Start Time End Time Duration (Hrs) Recorded By
11/04/2025 ELX-1015 Post-mixing 09:00 AM 04:30 PM 7.5 Rajesh Kumar

Annexure-2: Holding Condition Checklist

Condition Compliance (Yes/No) Remarks Checked By
Temperature maintained at 20–25°C Yes Within range Sunita Reddy
Container closed and labeled Yes Tag updated Sunita Reddy

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
01/01/2024 1.0 Initial Release New SOP QA Head
11/04/2025 2.0 Included separate holding limits for intermediate and bulk Process Optimization QA Head
Elixers V 2.0 Tags:Elixir colorants, Elixir dosage form, Elixir filtration techniques, Elixir flavoring agents, Elixir formulation, Elixir GMP compliance, Elixir manufacturing process, Elixir manufacturing SOPs, Elixir packaging requirements, Elixir pharmacopoeial standards, Elixir preparation methods, Elixir preservatives, Elixir production equipment, Elixir quality control, Elixir regulatory guidelines, Elixir shelf life, Elixir stability testing, Elixir sterilization methods, Elixir storage conditions, Elixir sweetening agents, Elixir viscosity modifiers, Hydroalcoholic solutions, Medicated elixirs, Non-medicated elixirs, Pharmaceutical elixirs

Post navigation

Previous Post: Creams: SOP for Calibration of Viscometers for Cream Testing – V 2.0
Next Post: API Manufacturing: SOP for Review and Archiving of Analytical Data – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version